Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy
Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy
复制标题
DOI：
10.3109/13697137.2011.620658
复制
发表时间：
2012-08-01
期刊：
影响因子：
2.8
通讯作者：
Helzlsouer, K. J.
中科院分区：
文献类型：
--
作者：
Gallicchio, L.;MacDonald, R.;Helzlsouer, K. J.
目的比较服用芳香酶抑制剂(AIs)的乳腺癌患者和未被诊断为癌症的同龄女性的更年期症状，并确定乳腺癌患者在接受AI治疗的前6个月中出现这些症状的比例是否发生了变化。方法对100名开始接受AI治疗的乳腺癌患者和200名年龄相近的无癌症病史的女性进行为期6个月的队列研究。在基线(乳腺癌患者接受人工智能治疗前)、3个月和6个月，对参与者进行全面的问卷调查，以确定特定更年期症状的体验数据。结果数据显示，乳腺癌患者某些症状的患病率从基线到任何一个随访点都有统计学意义的增加；这些症状包括潮热、盗汗、性交疼痛、脱发、健忘、抑郁、入睡困难和睡眠中断。此外，乳腺癌患者在随访期间比对照组女性更容易报告许多相同症状的新发作。结论由于烦人的症状和副作用是导致停止和不坚持治疗的主要原因，肿瘤学家应该监测和解决症状，以便乳腺癌患者能够保持她的生活质量，并保持对治疗计划的遵守。
Objectives To examine self-reported menopausal-type symptoms among breast cancer patients on aromatase inhibitors (AIs) compared to women of the same age who had not been diagnosed with cancer, and to determine whether the percentage of breast cancer patients experiencing these symptoms changed over the first 6 months of AI treatment.Methods Data from a 6-month cohort study of 100 breast cancer patients initiating AI therapy and of 200 women of a similar age without a history of cancer were analyzed. At baseline (prior to the initiation of AI therapy among the breast cancer patients), 3 months, and 6 months, a comprehensive questionnaire was administered to participants that ascertained data on the experiencing of specific menopausal-type symptoms.Results The data showed statistically significant increases in the prevalence of certain symptoms from baseline to either follow-up point among the breast cancer patients; these symptoms included hot flushes, night sweats, pain during intercourse, hair loss, forgetfulness, depression, difficulty falling asleep, and interrupted sleep. Additionally, breast cancer patients were more likely than the women in the comparison group to report the new onset of many of these same symptoms during the follow-up time period.Conclusions Because bothersome symptoms and side-effects are a major reason for discontinuation and non-adherence to treatment, symptoms should be monitored and addressed by oncologists so that the breast cancer patient can maintain her quality of life and remain adherent to the treatment schedule.